$6.950
-0.232 (-3.34%)收盤時
PGEN 資訊
PGEN 事件
Precigen Reports $53.1M Net Revenue in Q2
For Precigen, the second quarter marked a commercial inflection. PAPZIMEOS generated $53.1 M in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability. President and CEO Helen Sabzevari, PhD, framed the quarter as platform validation. "PAPZIMEOS demonstrates the AdenoVerse platform's ability to target HPV-associated diseases. We are building on that validated capability by advancing PRGN-2009 in HPV-driven cancers," she said.
Precigen Reports Q2 Revenue of $55.0M, Exceeding Expectations
Reports Q2 revenue $55.0M, consensus $27.83M. "We delivered a historic Q2, with the rapid adoption of PAPZIMEOS demonstrating the strength of our groundbreaking science and innovative commercial strategy," said Helen Sabzevari, President and CEO of Precigen. "This momentum provides a strong foundation for our next phase of growth as we work to expand PAPZIMEOS globally and into the pediatric population. PAPZIMEOS demonstrates the AdenoVerse platform's ability to target HPV-associated diseases. We are building on that validated capability by advancing PRGN-2009 in HPV-driven cancers, with a pipeline update expected by year-end. With growing commercial momentum, a validated platform, and multiple opportunities ahead, we believe Precigen is well positioned to deliver sustained value for patients across various indications, the broader healthcare community, and our shareholders."
Precigen Updates Papzimeos Study Data
Precigen announced updated long-term follow-up data from the study of Papzimeos for the treatment of adults with recurrent respiratory papillomatosis, RRP. Updated durability of response data were presented at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago in a presentation titled, "Zopapogene imadenovec-drba, a novel non-replicating adenoviral vector-based immunotherapy: Effects on complete and durable responses in recurrent respiratory papillomatosis pivotal trial." Key data highlights from the ASCO presentation include: 15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses as of the April 30, 2026 data cutoff; Patients did not receive any additional treatments for RRP; All complete responders had at least 36 months of follow-up, with a median follow-up of 36 months and a mean follow-up of 40 months; 5 complete responders have ongoing responses beyond 4 years; Median duration of complete response has not yet been reached; and No new safety events were observed during long-term follow-up.
Precigen Receives FDA Orphan Drug Exclusivity for Papzimeos
Precigen announced that the FDA has granted orphan drug exclusivity for papzimeos - zopapogene imadenovec-drba - for the treatment of adults with recurrent respiratory papillomatosis, or RRP. Papzimeos was granted full approval by the FDA in August 2025, becoming the first and only approved treatment for adults with RRP, a rare, chronic and debilitating disease. Papzimeos is commercially available in the US and is being prescribed nationwide across both major medical centers and community practices. Orphan drug exclusivity is granted to certain drugs and biologics approved for rare diseases or conditions that affect fewer than 200,000 people in the U.S. The orphan drug exclusivity granted by the FDA for papzimeos for the treatment of adults with RRP is effective through August 14, 2032, providing seven years of market exclusivity in the U.S. RRP is a rare, debilitating, and potentially life-threatening disease of the upper and lower respiratory tract that can lead to severe voice disturbance, compromised airways, and recurrent post-obstructive pneumonia.
Company Reports Q1 Revenue of $23.25M, Exceeds Expectations
Reports Q1 revenue $23.25M, consensus $20.8M. "We are thrilled with the strength of the PAPZIMEOS launch and the pace of revenue growth as we drive broad commercial success across the US and work toward expanded market opportunities in additional geographies and the pediatric patient population," said Helen Sabzevari, CEO. "Looking ahead, we are excited to advance the next chapter of our AdenoVerse platform through the continued development of PRGN-2009 in HPV-associated cancers, and look forward to sharing more details on our broader pipeline progress later this year." "We are pleased with the launch performance of PAPZIMEOS, recognizing $21.6M of net revenue in the first full quarter of its launch. In the second quarter of 2026, we are seeing continued strength in revenue growth from PAPZIMEOS," said CFO Harry Thomasian Jr. "As of March 31, 2026, the Company's cash, cash equivalents, and investments totaled $56.7M, which based on payment terms, did not include any collection of PAPZIMEOS related accounts receivable since launch of approximately $25.7M. Based on our current revenue outlook and present financial forecast, we continue to believe that our current cash position and anticipated cash to be received from PAPZIMEOS sales will fund operations through cash flow break-even by the end of 2026".
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。